{
    "nctId": "NCT00087958",
    "briefTitle": "Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment",
    "officialTitle": "Phase II Multi-Center, Open-Label, Non-Randomized Study of Intravenous RPR109881 Given Every 3 Weeks in Patients With Metastatic Breast Cancer Progressing After Therapy With Anthracyclines, Taxanes and Capecitabine",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 168,
    "primaryOutcomeMeasure": "Objective response rate as assessed by Response Evaluation Criteria in Solid Tumors",
    "eligibilityCriteria": "Inclusion Criteria:\n\nIn order to be eligible for this trial you must:\n\n* Have a diagnosis of breast cancer that is now metastatic (meaning the cancer has spread beyond its original location) or a recurrence of the cancer in its original location that cannot be removed by surgery.\n* Have received previous treatment with anthracyclines (e.g. doxorubicin \\[Adriamycin or Doxil\\] or epirubicin \\[Ellence\\]), taxanes (paclitaxel \\[Taxol or Abraxane\\] or docetaxel \\[Taxotere\\]) and capecitabine (e.g. Xeloda) for your breast cancer and your doctor has determined that these treatments are no longer of benefit to you.\n* Be at least 18 years of age\n* Not be taking other treatments for your cancer at the time you enter the trial.\n* Not be pregnant\n* Additionally, there are other criteria for study entry that a doctor participating in this study will need to review in detail with you and clinical assessments may need to be performed (lab tests, CT scans).\n\nExclusion Criteria:\n\n* None listed here. Can be discussed with your doctor.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}